In this context, the United States Food and Drug Administration (FDA) has validated mesothelin as a useful marker in malignant pleural mesothelioma, contributing to the assessment of response to chemotherapy and detection of recurrences [22,23]. This evidence concerns the gene MSLN and malignant pleural mesothelioma.